The novel role of IL-37 to enhance the anti-inflammatory response of regulatory T cells in patients with peripheral atherosclerosis
Authors:
- 4 May 2020
- journal article
- research article
- Published by SAGE Publications in Vascular
- Vol. 28 (5) , 629-642
Abstract
Objectives: Regulatory T cells (Tregs) mediate immunomodulation and protect against atherosclerosis. It is considered that reducing the amount of pro-inflammatory mediators could be achieved by enhancing the anti-inflammatory response, and this may be considered one of the main targets for therapy development. The inhibitory cytokines secreted by Tregs mainly include interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β). Based on its known immunosuppressive involvement with other inflammatory disorders, we hypothesized that the newly characterized cytokine interleukin-37 (IL-37) might be associated with the inhibitory functions of Treg in atherosclerosis. Immune regulatory functions of IL-37 have not been completely clarified. Accordingly, we speculated that IL-37 might play a regulatory role in the immunosuppression of Tregs in atherosclerotic disease. Methods: Real-time polymerase chain reaction and enzyme linked immunosorbent assay were used to test gene expression and protein levels of IL-37 in peripheral blood and localized freshly resected arterial tissues from 84 patients with peripheral arterial occlusive disease and 50 non-atherosclerotic subjects. Results were correlated to disease hallmarks. We also evaluated the ability of recombinant IL-37 to modulate Treg cytokine secretion and T cell inhibition in relation to atherosclerotic disorder in vitro. Results: Our results revealed that IL-37 was increased in patients with chronic lower limb atherosclerotic ischemia, compared to non-atherosclerotic controls. In addition, the expression levels of circulating IL-37 correlated with disease severity of chronic lower limb ischemia. Supplementation with rIL-37 augmented levels of released IL-10 and TGF-β in supernatants of T cells co-cultured with Tregs in the enrolled patients. Conclusions: Results suggest a role for IL-37 in mediating anti-inflammatory functions in the atherosclerotic process, potentially involving enhancement of Treg inhibitory function and anti-inflammatory cytokine secretion with a particularly marked direct response in severe disease.Keywords
This publication has 35 references indexed in Scilit:
- Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in miceClinical and Experimental Immunology, 2014
- Immune Effector Mechanisms Implicated in Atherosclerosis: From Mice to HumansImmunity, 2013
- The Biological Role of Inflammation in AtherosclerosisCanadian Journal of Cardiology, 2012
- TGF-β inhibits the uptake of modified low density lipoprotein by human macrophages through a Smad-dependent pathway: A dominant role for Smad-2Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Interleukin 37 expression protects mice from colitisProceedings of the National Academy of Sciences, 2011
- IL-37 is a fundamental inhibitor of innate immunityNature Immunology, 2010
- CTLA‐4 is required by CD4+CD25+ Treg to control CD4+ T‐cell lymphopenia‐induced proliferationEuropean Journal of Immunology, 2009
- Isolation of Whole Mononuclear Cells from Peripheral Blood and Cord BloodCurrent Protocols in Immunology, 2009
- Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)Journal of Vascular Surgery, 2007
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999